1. Home
  2. RLMD vs ELUT Comparison

RLMD vs ELUT Comparison

Compare RLMD & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RLMD
  • ELUT
  • Stock Information
  • Founded
  • RLMD 2004
  • ELUT 2015
  • Country
  • RLMD United States
  • ELUT United States
  • Employees
  • RLMD N/A
  • ELUT N/A
  • Industry
  • RLMD Biotechnology: Pharmaceutical Preparations
  • ELUT Medical Specialities
  • Sector
  • RLMD Health Care
  • ELUT Health Care
  • Exchange
  • RLMD Nasdaq
  • ELUT Nasdaq
  • Market Cap
  • RLMD 67.7M
  • ELUT 79.7M
  • IPO Year
  • RLMD N/A
  • ELUT 2020
  • Fundamental
  • Price
  • RLMD $2.09
  • ELUT $0.89
  • Analyst Decision
  • RLMD Hold
  • ELUT Strong Buy
  • Analyst Count
  • RLMD 2
  • ELUT 2
  • Target Price
  • RLMD $1.00
  • ELUT $7.00
  • AVG Volume (30 Days)
  • RLMD 335.3K
  • ELUT 318.3K
  • Earning Date
  • RLMD 11-07-2025
  • ELUT 11-06-2025
  • Dividend Yield
  • RLMD N/A
  • ELUT N/A
  • EPS Growth
  • RLMD N/A
  • ELUT N/A
  • EPS
  • RLMD N/A
  • ELUT N/A
  • Revenue
  • RLMD N/A
  • ELUT $23,683,000.00
  • Revenue This Year
  • RLMD N/A
  • ELUT $1.90
  • Revenue Next Year
  • RLMD N/A
  • ELUT $6.37
  • P/E Ratio
  • RLMD N/A
  • ELUT N/A
  • Revenue Growth
  • RLMD N/A
  • ELUT N/A
  • 52 Week Low
  • RLMD $0.24
  • ELUT $0.85
  • 52 Week High
  • RLMD $3.98
  • ELUT $5.12
  • Technical
  • Relative Strength Index (RSI)
  • RLMD 55.74
  • ELUT 28.97
  • Support Level
  • RLMD $1.98
  • ELUT $0.86
  • Resistance Level
  • RLMD $2.27
  • ELUT $0.95
  • Average True Range (ATR)
  • RLMD 0.21
  • ELUT 0.05
  • MACD
  • RLMD -0.04
  • ELUT 0.04
  • Stochastic Oscillator
  • RLMD 64.22
  • ELUT 27.18

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Share on Social Networks: